

# Thomas Filleron

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7527367/thomas-filleron-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188  
papers

5,458  
citations

37  
h-index

68  
g-index

242  
ext. papers

6,841  
ext. citations

4.5  
avg, IF

5.18  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 188 | Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 5678-87   | 10.1 | 300       |
| 187 | Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). <i>Lancet Oncology</i> , <b>2014</b> , 15, 267-74   | 21.7 | 282       |
| 186 | Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 992-9   | 2.2  | 266       |
| 185 | Genomic characterization of metastatic breast cancers. <i>Nature</i> , <b>2019</b> , 569, 560-564   | 50.4 | 256       |
| 184 | Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002201  | 20.1 | 214       |
| 183 | Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1403-1410  | 2.2  | 198       |
| 182 | Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. <i>Annals of Oncology</i> , <b>2016</b> , 27, 281-6  | 10.3 | 187       |
| 181 | TNF $\alpha$ blockade overcomes resistance to anti-PD-1 in experimental melanoma. <i>Nature Communications</i> , <b>2017</b> , 8, 2256  | 17.4 | 175       |
| 180 | High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. <i>OncImmunology</i> , <b>2012</b> , 1, 829-839   | 7.2  | 128       |
| 179 | DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 13390-5 | 11.5 | 116       |
| 178 | Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1451-7  | 8.9  | 110       |
| 177 | CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. <i>Modern Pathology</i> , <b>2012</b> , 25, 1551-8   | 9.8  | 102       |
| 176 | Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2008-2017   | 2.2  | 98        |
| 175 | Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. <i>Radiation Oncology</i> , <b>2013</b> , 8, 1  | 4.2  | 95        |
| 174 | High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin B-producing dendritic cells in human breast cancer. <i>Journal of Immunology</i> , <b>2013</b> , 191, 2001-8   | 5.3  | 93        |
| 173 | Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) <i>Annals of Oncology</i> , <b>2015</b> , 26, 873-879                       | 10.3 | 89        |
| 172 | Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. <i>JAMA Otolaryngology</i> , <b>2010</b> , 136, 1219-25   |      | 86        |

|     |  |      |    |
|-----|--|------|----|
| 171 | Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). <i>European Journal of Cancer</i> , <b>2016</b> , 56, 77-84   | 7.5  | 83 |
| 170 | Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. <i>Nature Communications</i> , <b>2013</b> , 4, 1840   | 17.4 | 83 |
| 169 | CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. <i>Oncotarget</i> , <b>2017</b> , 6, e1331193  | 7.2  | 80 |
| 168 | Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E9346-E9355  | 11.5 | 72 |
| 167 | Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1337-43   | 3.5  | 71 |
| 166 | Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1595-1601   | 8.9  | 69 |
| 165 | Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 896-908                                    | 6.7  | 57 |
| 164 | Cell-assisted lipotransfer: Friend or foe in fat grafting? Systematic review and meta-analysis. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , <b>2018</b> , 12, e1237-e1250   | 4.4  | 56 |
| 163 | Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1042  | 7.1  | 54 |
| 162 | Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. <i>Nature Communications</i> , <b>2020</b> , 11, 437   | 17.4 | 53 |
| 161 | The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 509-21   | 13.4 | 52 |
| 160 | Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. <i>Modern Pathology</i> , <b>2017</b> , 30, 1677-1687   | 9.8  | 51 |
| 159 | A Systematic Review and Meta-Analysis of Double Venous Anastomosis in Free Flaps. <i>Plastic and Reconstructive Surgery</i> , <b>2015</b> , 136, 1299-1311   | 2.7  | 51 |
| 158 | Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. <i>Oncotarget</i> , <b>2017</b> , 8, 86947-86968  | 3.3  | 49 |
| 157 | Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 391-397  | 4.9  | 43 |
| 156 | Anatomical correlates for category-specific naming of objects and actions: a brain stimulation mapping study. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 429-43  | 5.9  | 41 |
| 155 | Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 769-81 | 7.5  | 40 |
| 154 | Laparoscopic pelvic exenteration for gynaecological malignancy: is there any advantage?. <i>Gynecologic Oncology</i> , <b>2011</b> , 120, 374-9  | 4.9  | 39 |

|     |   |      |    |
|-----|---|------|----|
| 153 | Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2161-9                                  | 7.5  | 38 |
| 152 | Accuracy of intraoperative pathological examination of SLN in cervical cancer. <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 525-9   | 4.9  | 38 |
| 151 | The AF-1-deficient estrogen receptor ER $\alpha$ isoform is frequently expressed in human breast tumors. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 123  | 8.3  | 36 |
| 150 | Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. <i>Cancer Research</i> , <b>2011</b> , 71, 4068-73  | 10.1 | 36 |
| 149 | Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , <b>2015</b> , 26, 865-872  | 10.3 | 34 |
| 148 | Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 337-343 | 4    | 33 |
| 147 | Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2017</b> , 169, 210-218   | 5.1  | 32 |
| 146 | Detection of local recurrences of limb soft tissue sarcomas: is magnetic resonance imaging (MRI) relevant?. <i>European Journal of Radiology</i> , <b>2009</b> , 72, 50-3   | 4.7  | 29 |
| 145 | Brachytherapy in lip carcinoma: long-term results. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, e839-43   | 4    | 28 |
| 144 | Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 250-255  | 50.5 | 28 |
| 143 | PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress. <i>Science Signaling</i> , <b>2016</b> , 9, ra44   | 8.8  | 27 |
| 142 | Key contribution of eIF4H-mediated translational control in tumor promotion. <i>Oncotarget</i> , <b>2015</b> , 6, 39924-340   | 3.3  | 26 |
| 141 | Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. <i>Quality of Life Research</i> , <b>2016</b> , 25, 1713-23  | 3.7  | 25 |
| 140 | Prediction of early breast cancer metastasis from DNA microarray data using high-dimensional cox regression models. <i>Cancer Informatics</i> , <b>2015</b> , 14, 129-38  | 2.4  | 25 |
| 139 | Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review. <i>Journal of Nutrition, Health and Aging</i> , <b>2016</b> , 20, 878-888   | 5.2  | 24 |
| 138 | Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. <i>BMC Cancer</i> , <b>2019</b> , 19, 167  | 4.8  | 23 |
| 137 | Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 76-82   | 4.3  | 23 |
| 136 | Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 356-365   | 3.1  | 23 |

|     |  |      |    |
|-----|--|------|----|
| 135 | Total body irradiation using Helical Tomotherapy: Treatment technique, dosimetric results and initial clinical experience. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , <b>2018</b> , 22, 17-24   | 1.3  | 22 |
| 134 | Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. <i>Health and Quality of Life Outcomes</i> , <b>2014</b> , 12, 69   | 3    | 22 |
| 133 | Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project <i>Annals of Oncology</i> , <b>2015</b> , 26, 2392-8  | 10.3 | 22 |
| 132 | RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R6   | 8.3  | 22 |
| 131 | Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4434-45 | 12.9 | 22 |
| 130 | Perception of lung cancer among the general population and comparison with other cancers. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 420-5  | 8.9  | 21 |
| 129 | RhoB promotes cancer initiation by protecting keratinocytes from UVB-induced apoptosis but limits tumor aggressiveness. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 203-212   | 4.3  | 21 |
| 128 | Single domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naïve libraries. <i>Developmental and Comparative Immunology</i> , <b>2012</b> , 36, 150-6   | 3.2  | 20 |
| 127 | Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 793-9           | 4    | 20 |
| 126 | hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. <i>Oncotarget</i> , <b>2016</b> , 7, 16793-805  | 3.3  | 20 |
| 125 | The frontal branch of the facial nerve: can we define a safety zone?. <i>Surgical and Radiologic Anatomy</i> , <b>2015</b> , 37, 499-506   | 1.4  | 19 |
| 124 | Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer. <i>BMC Urology</i> , <b>2016</b> , 16, 26  | 2.2  | 19 |
| 123 | A large retrospective multicenter study of vaginal melanomas: implications for new management. <i>Melanoma Research</i> , <b>2013</b> , 23, 138-46   | 3.3  | 19 |
| 122 | Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1828-1835  | 10.3 | 18 |
| 121 | Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1264-71   | 12.9 | 18 |
| 120 | Dermatofibrosarcoma protuberans: margins reduction using slow-Mohs micrographic surgery. Experience with 35 patients. <i>Annales De Chirurgie Plastique Et Esthetique</i> , <b>2014</b> , 59, 219-25   | 1.1  | 17 |
| 119 | Surgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2515-21  | 3.1  | 17 |
| 118 | Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 535-541   | 3.1  | 16 |

|     |  |         |
|-----|--|---------|
| 117 | RhoB determines tumor aggressiveness in a murine EGFR <sup>L858R</sup> -induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6541-50 <sup>12.9</sup>  | 16      |
| 116 | Long-term oncological outcome after endoscopic surgery for olfactory esthesioneuroblastoma. <i>Acta Oto-Laryngologica</i> , <b>2014</b> , 134, 1259-64   | 1.6 16  |
| 115 | Prognosis and ICU outcome of systemic vasculitis. <i>BMC Anesthesiology</i> , <b>2013</b> , 13, 27   | 2.4 16  |
| 114 | Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAF <sup>i</sup> -Resistant Melanomas. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 289-300  | 6.1 16  |
| 113 | Inhibiting Integrin $\beta$ to Differentiate and Radiosensitize Glioblastoma-Initiating Cells. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 384-397  | 6.6 16  |
| 112 | Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 443   | 5.6 15  |
| 111 | IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 903-911  | 4 15    |
| 110 | External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis. <i>European Journal of Cancer</i> , <b>2017</b> , 72, 200-209  | 7.5 14  |
| 109 | Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control. <i>Strahlentherapie Und Onkologie</i> , <b>2015</b> , 191, 225-33   | 4.3 14  |
| 108 | Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. <i>Haematologica</i> , <b>2020</b> , 105, e480-483  | 6.6 14  |
| 107 | Comparison of variable selection methods for high-dimensional survival data with competing events. <i>Computers in Biology and Medicine</i> , <b>2017</b> , 91, 159-167  | 7 13    |
| 106 | The 21-gene Recurrence Score <sup>®</sup> assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). <i>BMC Cancer</i> , <b>2018</b> , 18, 526 | 4.8 13  |
| 105 | Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 129-37  | 8.8 13  |
| 104 | Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1037-1047   | 12.9 13 |
| 103 | Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. <i>Oncologist</i> , <b>2015</b> , 20, 62-71   | 5.7 12  |
| 102 | Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 145, 109-116   | 5.3 12  |
| 101 | Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , <b>2016</b> , 76, 5954-5961   | 10.1 12 |
| 100 | Retrospective analysis of local control and cosmetic outcome of 147 periorificial carcinomas of the face treated with low-dose rate interstitial brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 726-31  | 4 12    |



|    |  |      |    |
|----|--|------|----|
| 99 | Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 7422-30   | 12.9 | 12 |
| 98 | Anti-TNF, a magic bullet in cancer immunotherapy? <b>2019</b> , 7, 303   |      | 12 |
| 97 | Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e277-e285   | 4.9  | 12 |
| 96 | PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 177, 659-667   | 4.4  | 11 |
| 95 | Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study. <i>Histopathology</i> , <b>2014</b> , 64, 274-83  | 7.3  | 11 |
| 94 | Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 124, 465-73   | 4.8  | 11 |
| 93 | Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 78, 95-100  | 5.3  | 11 |
| 92 | How to report toxicity associated with targeted therapies?. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1633-8   | 10.3 | 11 |
| 91 | Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: the METAL3 Study. <i>Contemporary Clinical Trials</i> , <b>2015</b> , 40, 1-8   | 2.3  | 10 |
| 90 | Prognostic relevance of celiac lymph node involvement in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 48-53  | 3.5  | 10 |
| 89 | An R function to non-parametric and piecewise analysis of competing risks survival data. <i>Computer Methods and Programs in Biomedicine</i> , <b>2010</b> , 100, 24-38  | 6.9  | 10 |
| 88 | Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 585-595   | 6.1  | 10 |
| 87 | New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage. <i>Brachytherapy</i> , <b>2018</b> , 17, 544-555  | 2.4  | 9  |
| 86 | Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R. <i>Computer Methods and Programs in Biomedicine</i> , <b>2016</b> , 125, 79-87   | 6.9  | 9  |
| 85 | Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 651-8   | 4    | 9  |
| 84 | Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure?: a single-center review of patients with extraluminal pelvic recurrence for rectal cancer from March 2004 to November 2010. <i>American Journal of Surgery</i> , <b>2015</b> , 209, 352-62 | 2.7  | 9  |
| 83 | Recurrence risk after Ivor Lewis oesophagectomy for cancer. <i>Journal of Cardiothoracic Surgery</i> , <b>2013</b> , 8, 215  | 1.6  | 9  |
| 82 | Abstract GS3-02: Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase II randomized trial SAFIR02-IMMUNO <b>2020</b> ,  |      | 9  |

|    |  |      |   |
|----|--|------|---|
| 81 | Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 568-582   | 12.5 | 9 |
| 80 | Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 1244-1255                       | 6.1  | 9 |
| 79 | Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study. <i>BMC Medical Genomics</i> , <b>2015</b> , 8, 3   | 3.7  | 8 |
| 78 | Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma. <i>BJU International</i> , <b>2016</b> , 117, 444-9  | 5.6  | 8 |
| 77 | Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?. <i>Histopathology</i> , <b>2018</b> , 73, 969-982 | 7.3  | 8 |
| 76 | The $\beta$ /focal adhesion kinase/glycogen synthase kinase 3 $\beta$ integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy. <i>Human Pathology</i> , <b>2013</b> , 44, 2149-58     | 3.7  | 8 |
| 75 | External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer. <i>BJU International</i> , <b>2014</b> , 114, E113-E119  | 5.6  | 8 |
| 74 | Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147787  | 3.7  | 7 |
| 73 | Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 193-199   | 8.7  | 7 |
| 72 | Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 505-513   | 4.4  | 6 |
| 71 | Role of radiation therapy in the conservative management of sarcoma within an irradiated field. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 187-92  | 3.6  | 6 |
| 70 | Planning posttherapeutic oncology surveillance visits based on individual risk. <i>Medical Decision Making</i> , <b>2009</b> , 29, 570-9   | 2.5  | 6 |
| 69 | Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 41  | 7.8  | 6 |
| 68 | The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1588-1593                         | 10.3 | 5 |
| 67 | Comparing sensitivity and specificity of medical imaging tests when verification bias is present: The concept of relative diagnostic accuracy. <i>European Journal of Radiology</i> , <b>2018</b> , 98, 32-35  | 4.7  | 5 |
| 66 | Measurement of inter- and intra-observer variability in the routine clinical interpretation of brain 18-FDG PET-CT. <i>Annals of Nuclear Medicine</i> , <b>2015</b> , 29, 233-9  | 2.5  | 5 |
| 65 | What to expect from molecular tools for non-documented pediatric infectious diseases. <i>Expert Review of Molecular Diagnostics</i> , <b>2015</b> , 15, 1645-56  | 3.8  | 5 |
| 64 | Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary. <i>Journal of Gynecologic Oncology</i> , <b>2011</b> , 22, 9-17   | 4    | 5 |



|    |  |      |   |
|----|--|------|---|
| 63 | Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers. <i>Blood</i> , <b>2017</b> , 130, 652-652                                   | 2.2  | 5 |
| 62 | 128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial. <i>Annals of Oncology</i> , <b>2020</b> , 31, S58-S59                   | 10.3 | 5 |
| 61 | Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. <i>ESMO Open</i> , <b>2021</b> , 6, 100106  | 6    | 5 |
| 60 | Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience. <i>Breast Journal</i> , <b>2016</b> , 22, 510-9  | 1.2  | 5 |
| 59 | Prospective evaluation of the performances of narrow-band imaging flexible videoscopy relative to white-light imaging flexible videoscopy, in patients scheduled for transurethral resection of a primary NMIBC. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1615-1621 | 4    | 5 |
| 58 | Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. <i>BMC Cancer</i> , <b>2019</b> , 19, 809  | 4.8  | 4 |
| 57 | Gofte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models. <i>Computer Methods and Programs in Biomedicine</i> , <b>2019</b> , 177, 269-275   | 6.9  | 4 |
| 56 | Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. <i>Current Clinical Pharmacology</i> , <b>2011</b> , 6, 274-9  | 2.5  | 4 |
| 55 | Personalised cancer follow-up: risk stratification, needs assessment or both?. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1579-80   | 8.7  | 4 |
| 54 | Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 716   | 4.8  | 4 |
| 53 | Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1879-1887   | 4.3  | 3 |
| 52 | Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals. <i>Statistics in Medicine</i> , <b>2017</b> , 36, 362-377  | 2.3  | 3 |
| 51 | Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling. <i>Medical Decision Making</i> , <b>2014</b> , 34, 168-79  | 2.5  | 3 |
| 50 | Designing group sequential randomized clinical trials with time to event end points using a R function. <i>Computer Methods and Programs in Biomedicine</i> , <b>2012</b> , 108, 113-28  | 6.9  | 3 |
| 49 | Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up. <i>Bulletin Du Cancer</i> , <b>2012</b> , 99, E64-74   | 2.4  | 3 |
| 48 | Prognostic factors of young women (B5 years) with node positive breast cancer: possible influence on post-therapeutic follow-up. <i>Bulletin Du Cancer</i> , <b>2013</b> , 100, 22-9   | 2.4  | 3 |
| 47 | Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238795   | 3.7  | 3 |
| 46 | Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 577-585   | 4.4  | 3 |

|    |  |      |   |
|----|--|------|---|
| 45 | Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 120-126   | 7.5  | 3 |
| 44 | Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses. <i>Statistical Methods in Medical Research</i> , <b>2016</b> , 25, 2457-2471  | 2.3  | 2 |
| 43 | The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , <b>2019</b> , 16, 34-39 | 4.6  | 2 |
| 42 | Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R. <i>Computer Methods and Programs in Biomedicine</i> , <b>2015</b> , 118, 298-308  | 6.9  | 2 |
| 41 | What risk of prostate cancer led urologist to recommend prostate biopsies?. <i>Progres En Urologie</i> , <b>2015</b> , 25, 1125-31   | 0.9  | 2 |
| 40 | DNA polymerase $\beta$ gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status. <i>Haematologica</i> , <b>2018</b> , 103, 1038-1046  | 6.6  | 2 |
| 39 | Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment. <i>Radiation Oncology</i> , <b>2014</b> , 9, 247   | 4.2  | 2 |
| 38 | Laparoscopic observation of the diaphragm undersurface in the staging of peritoneal carcinomatosis: comparison of three optical systems. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2012</b> , 164, 65-8                          | 2.4  | 2 |
| 37 | The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy. <i>Clinical Lung Cancer</i> , <b>2012</b> , 13, 59-67   | 4.9  | 2 |
| 36 | Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. <i>Breast Cancer Research</i> , <b>2021</b> , 23, 61  | 8.3  | 2 |
| 35 | Feasibility of comprehensive genotyping specimens from radial endobronchial ultrasonography and electromagnetic navigation bronchoscopy. <i>ERJ Open Research</i> , <b>2021</b> , 7,   | 3.5  | 2 |
| 34 | VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 759-764  | 3.6  | 2 |
| 33 | Statistical controversies in clinical research: should schedules of tumor size assessments be changed?. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1981-1987  | 10.3 | 2 |
| 32 | Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 66-74  | 3.2  | 2 |
| 31 | Impact of a comprehensive geriatric assessment on decision-making in older patients with hematological malignancies. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 616-626   | 3.8  | 2 |
| 30 | Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model. <i>Journal of Contemporary Brachytherapy</i> , <b>2018</b> , 10, 463-469  | 1.9  | 2 |
| 29 | Gated F-FDG PET/CT of the Lung Using a Respiratory Spirometric Gating Device: A Feasibility Study. <i>Journal of Nuclear Medicine Technology</i> , <b>2019</b> , 47, 227-232   | 1.1  | 1 |
| 28 | Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. <i>European Journal of Cancer</i> , <b>2021</b> , 159, 283-295  | 7.5  | 1 |

|    |   |      |   |
|----|---|------|---|
| 27 | Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients. <i>Acta Dermato-Venereologica</i> , <b>2019</b> , 99, 1241-1245                           | 2.2  | 1 |
| 26 | A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. <i>Targeted Oncology</i> , <b>2021</b> , 16, 801-811         | 5    | 1 |
| 25 | Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings. <i>Computational and Mathematical Methods in Medicine</i> , <b>2020</b> , 2020, 6795392                                 | 2.8  | 1 |
| 24 | Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. <i>Pharmaceutical Research</i> , <b>2020</b> , 37, 147  | 4.5  | 1 |
| 23 | Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. <i>Respiratory Medicine and Research</i> , <b>2020</b> , 78, 100788                 | 1.4  | 1 |
| 22 | Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. <i>Cancer Medicine</i> , <b>2021</b> , 10, 2250-2258 | 4.8  | 1 |
| 21 | Nanobody-Based Quantification of GTP-Bound RHO Conformation Reveals RHOA and RHOC Activation Independent from Their Total Expression in Breast Cancer. <i>Analytical Chemistry</i> , <b>2021</b> , 93, 6104-6111      | 7.8  | 1 |
| 20 | Functional and oncological outcomes of salvage transoral robotic surgery: a comparative study. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2021</b> , 1  | 3.5  | 1 |
| 19 | Oncologic surveillance after curative treatment: A probability-based approach should be preferred to a risk-based approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 244-5  | 2.8  | 1 |
| 18 | Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol. <i>BMC Cancer</i> , <b>2019</b> , 19, 1153  | 4.8  | 1 |
| 17 | Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center. <i>International Journal of Cancer</i> , <b>2020</b> , 148, 2502              | 7.5  | 1 |
| 16 | Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package. <i>Computers in Biology and Medicine</i> , <b>2018</b> , 100, 239-246               | 7    | 1 |
| 15 | Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2139573     | 10.4 | 1 |
| 14 | Alternative methodological approach to randomized trial for surgical procedures routinely used. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 68, 109-115   | 2.3  | 0 |
| 13 | Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255017                         | 3.7  | 0 |
| 12 | Impact of surgery on survival in stage IV breast cancer. <i>Breast Journal</i> , <b>2017</b> , 23, 774  | 1.2  |   |
| 11 | R cidives pelviennes de cancers du rectum ^ composante extraluminale. <i>Oncologie</i> , <b>2015</b> , 17, 309-314  | 1    |   |
| 10 | Focus on an infrequently used quantity in the context of competing risks: The conditional probability function. <i>Computers in Biology and Medicine</i> , <b>2018</b> , 101, 70-81                                   | 7    |   |

|   |  |     |
|---|--|-----|
| 9 | A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 230-236   | 3.3 |
| 8 | Breast imaging: understanding how accuracy is measured when lesion are the unit of analysis. <i>Breast Journal</i> , <b>2013</b> , 19, 225-6   | 1.2 |
| 7 | Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment. <i>Strahlentherapie Und Onkologie</i> , <b>2021</b> , 197, 1051-1062                               | 4.3 |
| 6 | Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine. <i>Blood</i> , <b>2018</b> , 132, 1467-1467   | 2.2 |
| 5 | TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine. <i>Blood</i> , <b>2018</b> , 132, 2745-2745   | 2.2 |
| 4 | Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS3159-TPS3159                     | 2.2 |
| 3 | Intérêt des modèles de guérison dans le cadre des essais d'immunothérapie. <i>Revue DEpidemiologie Et De Sante Publique</i> , <b>2019</b> , 67, S141-S142  | 0.6 |
| 2 | Prise en charge des patients atteints d'un cancer bronchopulmonaire à petites cellules de stade IV : Analyse de la base nationale de données de vie réelle du programme Epidmio-Stratégie Médico-Économique (ESME). <i>Revue Des Maladies Respiratoires Actualites</i> , <b>2021</b> , 13, 120 | 0   |
| 1 | "Accelerated phase" chronic lymphocytic leukemia: still an intermediate risk disease in the era of targeted therapies.. <i>Hematological Oncology</i> , <b>2022</b> ,  | 1.3 |